Regeneron Pharmaceuticals (REGN) Institutional Ownership
13F filers reported holding 91.1% of Regeneron Pharmaceuticals (REGN) shares as of Jun 30, 2026, across 1,349 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 91.1%
- Jun 30, 2026
- 13F filers
- 1,349
- quarter ended Jun 30, 2026
- 13F value
- $58.8B
- 94.3M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Acquired · Option exercise | 1,500 | $726.53 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Acquired · Option exercise | 1,478 | $644.54 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Acquired · Option exercise | 905 | $492.00 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 439 | $939.57 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 575 | $940.46 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 982 | $941.58 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 1,215 | $942.31 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 529 | $943.53 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 108 | $944.22 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 35 | $945.61 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Open-market sale | 179 | $950.76 | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Option exercise | 905Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Option exercise | 1,478Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 4, 2026 | Pitofsky Jason | SVP Controller | Disposed · Option exercise | 1,500Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 3, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Disposed · Gift | 1,054 | — | ↗ |
| Nov 3, 2026 | Zoghbi Huda Y | director | Acquired · Option exercise | 7,439 | $380.95 | ↗ |
| Nov 3, 2026 | Zoghbi Huda Y | director | Disposed · Open-market sale | 6,939 | $970.42 | ↗ |
| Nov 3, 2026 | Zoghbi Huda Y | director | Disposed · Open-market sale | 500 | $971.06 | ↗ |
| Nov 3, 2026 | Zoghbi Huda Y | director | Disposed · Option exercise | 7,439Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 2, 2026 | Fenimore Christopher R. | EVP Finance CFO | Acquired · Option exercise | 6,000 | $381.92 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Regeneron Pharmaceuticals do institutions hold?
13F filers reported holding 91.1% of Regeneron Pharmaceuticals' shares as of Jun 30, 2026, across 1,349 filers.
How many 13F filers hold Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals was held by 1,349 13F filers as of Jun 30, 2026.
Not investment advice.

